GlassScriptPhysician profile
Michael W Carnahan
NPI 1871607903
$4,969.54
in general payments reported to CMS, 2019-2025
32 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $648 · 2021: $1,470 · 2022: $726 · 2023: $625 · 2024: $198 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.26 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $616.24 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $537.03 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $435.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $387.00 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $378.61 | 2019-2023 | |
| Amgen INC. | $353.54 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $353.39 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $328.06 | 2019-2022 | |
| Lilly USA, LLC | $306.61 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $155.55 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.64 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $73.16 | 2019 | |
| Merck Sharp & Dohme LLC | $65.93 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $60.99 | 2020-2023 | Austedo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $56.77 | 2020-2021 | |
| Pfizer INC. | $52.68 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $44.84 | 2019-2020 | |
| Boston Scientific Corporation | $44.46 | 2025 | Intracept |
| Corium, LLC | $44.07 | 2023-2024 | Azstarys |
| Biogen, INC. | $42.95 | 2021 | |
| Genentech USA, INC. | $41.23 | 2019 | |
| Allergan, INC. | $37.27 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $22.48 | 2019 | |
| Sanofi Pasteur INC. | $22.44 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.08 | 2021 | |
| Tactile Systems Technology INC | $20.66 | 2025 | Nimbl, Flexitouch Plus |
| Eisai INC. | $19.58 | 2021 | |
| Antares Pharma, INC. | $14.83 | 2020 | |
| Hologic Sales and Service, LLC | $14.53 | 2019 | |
| Mylan Specialty L.P. | $11.51 | 2021 | |
| Organon LLC | $7.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carnahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.